These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-003934-32 A Phase II, Randomized, Double Blind, Placebo-Controlled Study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 3010... 2007-08-29 due-trials
Ongoing, reported early 2007-005140-24 A Randomized, Double-Blind, Placebo-Controlled STudy to Assess Safety and Efficacy of ISIS 301012 Administration in Statin Intolerant Subjects not-yet-due
Exempt 2010-022239-12 A Phase 1b/2 Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), inPatients with Castrate-Resistant Prostate Cancer 2013-11-15 not-yet-due
Exempt Terminated 2010-022240-21 A Phase 1b/2 Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer 2012-12-14 not-yet-due
Not reported 2012-000833-38 A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation 2014-03-31 due-trials
Completed, report not yet due 2012-001831-30 A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy 2018-03-15 not-yet-due
Not reported 2012-001836-72 An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patient... 2014-08-13 due-trials
Reported results 2013-004422-29 A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscul... 2016-11-21 due-trials
Ongoing 2013-004561-13 An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) not-yet-due
Listed as ongoing, but also has a completion date 2014-000701-13 A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to P... 2015-11-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-001947-18 A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Later-onset Spinal Muscular A... 2017-02-22 bad-data
Listed as ongoing, but also has a completion date 2014-002421-35 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) 2017-03-27 bad-data
Listed as ongoing, but also has a completion date 2014-003434-93 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of 2017-01-24 bad-data
Ongoing 2015-000493-35 A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Partial Lipodystrophy not-yet-due
Other 2015-001870-16 An Open-label Extension Study for Patients with Spinal Muscular Atrophy who Previously Participated in Investigational Studies of ISIS 396443 not-yet-due
Not reported 2015-003337-10 A Double Blind, Placebo-Controlled, Phase 2A Mechanistic Study to Evaluate the Effect of ISIS 449884 (ISIS-GCGRRX an Antisense Inhibitor of the Glucagon Receptor) on Hepatic Lipid and Glycogen Content... 2017-05-22 due-trials
Ongoing 2015-003755-21 An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) not-yet-due
Exempt 2015-004003-23 A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered Subc... not-yet-due
Ongoing 2016-003373-18 A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to not-yet-due
Trial is outside EEC, and reported results 2017-000327-27 An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy bad-data
Trial is outside EEC, and reported results 2017-000621-12 A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy bad-data
Ongoing 2017-002165-21 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX an Antisense Inhibitor of Factor XI), ... not-yet-due
Completed, report not yet due 2017-003197-13 A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (ISIS-DGAT2RX, an Antisense Inhibitor of Diacylglycerol Acyltrans... 2018-11-28 not-yet-due
Ongoing 2017-004259-22 A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered On... not-yet-due
Listed as ongoing, but also has a completion date 2017-005115-13 A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3 2018-07-11 bad-data